Helicobacter pylori eradication and ulcer healing with daily lansoprazole, plus 1 or 2 weeks co-therapy with amoxycillin and clarithromycin

被引:13
作者
Louw, JA
Van Rensburg, CJ
Moola, S
Kotze, D
Marks, IN
机构
[1] Univ Cape Town, Gastrointestinal Unit, ZA-7700 Rondebosch, South Africa
[2] Groote Schuur Hosp, Gastrointestinal Clin, Cape Town, South Africa
[3] Groote Schuur Hosp, Dept Med, Cape Town, South Africa
[4] Univ Stellenbosch, ZA-7600 Stellenbosch, South Africa
[5] Tygerberg Hosp, Dept Med, Parowvallei, South Africa
[6] Addington Hosp, Dept Med, Durban, South Africa
[7] Univ Natal, Durban, South Africa
[8] Univ Western Cape, Dept Stat, ZA-7535 Bellville, South Africa
关键词
D O I
10.1046/j.1365-2036.1998.00382.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Proton pump inhibitor based combination therapy is one standard strategy for Helicobacter pylori eradication, Aim: To compare the eradication and duodenal ulcer healing efficacy of two 2-week, single dose, lansoprazole based combination therapies. Methods: Healthy adult patients with endoscopically confirmed, H. pylori associated duodenal ulcer disease (3 mm > ulcer < 20 mm) were eligible for the study. All patients received a 14 day course of lansoprazole 30 mg o.m., and were randomized to receive either 7 or 14 days of amoxycillin 1 g b.d. and clarithromycin 500 mg b.d. Patients were endoscoped at entry and 14-17 days later, Symptomatic, unhealed patients received a further 14 days of therapy with lansoprazole SO mg o.m. Eradication was confirmed a minimum of 28 days after cessation of all therapy by urease reaction and histological assessment of gastric body and antral biopsies (three biopsies each site). Results: Sixty-two patients were randomized to a treatment arm, of which 58 could be included in an intention-to-treat and key-point-available analysis. H. pylori eradication rates were identical, at 93% (95% CI: 73-98% (1 week), 78-99% (2 week)). In the combined group, all but 13 ulcers were healed at 2 weeks; six required further therapy because of symptoms, while six of the seven asymptomatic patients went on to heal. Conclusion: An eradication regimen, based on a 2-week course of single dose lansoprazole with 1 week of antibiotic co-therapy, is effective in eradicating H. pylori, while the 2 weeks of acid suppression is usually effective in duodenal ulcer healing.
引用
收藏
页码:881 / 885
页数:5
相关论文
共 10 条
[1]   SHORT-TERM TRIPLE TREATMENT OF HELICOBACTER-PYLORI INFECTION WITH PANTOPRAZOLE, CLARITHROMYCIN AND METRONIDAZOLE [J].
ADAMEK, RJ ;
SZYMANSKI, C ;
PFAFFENBACH, B ;
OPFERKUCH, W ;
RICKEN, D ;
WEGENER, M .
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1995, 120 (11) :358-360
[2]   SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI [J].
BAZZOLI, F ;
ZAGARI, RM ;
FOSSI, S ;
POZZATO, P ;
ALAMPI, G ;
SIMONI, P ;
SOTTILI, S ;
RODA, A ;
RODA, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) :773-777
[3]   Unhealed duodenal ulcers despite Helicobacter pylori eradication [J].
Gisbert, JP ;
Boixeda, D ;
DeArgila, CM ;
Baleriola, IA ;
Abraira, V ;
Plaza, AG .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (07) :643-650
[4]   Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection [J].
Harris, AW ;
Pryce, DI ;
Gabe, SM ;
Karim, QN ;
Walker, MM ;
Langworthy, H ;
Baron, JH ;
Misiewicz, JJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (06) :1005-1008
[5]   DUODENAL-ULCER HEALING BY ERADICATION OF HELICOBACTER-PYLORI WITHOUT ANTI-ACID TREATMENT - RANDOMIZED CONTROLLED TRIAL [J].
HOSKING, SW ;
LIN, TKW ;
CHUNG, SCS ;
YUNG, MY ;
CHENG, AFB ;
SUNG, JJY ;
LI, AKC .
LANCET, 1994, 343 (8896) :508-510
[6]  
Lind T, 1996, Helicobacter, V1, P138, DOI 10.1111/j.1523-5378.1996.tb00027.x
[7]  
Malfertheiner P, 1997, GUT, V41, P8
[8]  
MOAYYEDI P, 1995, EUR J GASTROEN HEPAT, V7, P835
[9]   Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection [J].
Tursi, A ;
Cammarota, G ;
Montalto, M ;
Papa, A ;
Veneto, G ;
Cuoco, L ;
Trua, F ;
Branca, G ;
Fedeli, G ;
Gasbarrini, G .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 1996, 10 (03) :285-288
[10]  
YOUSFI MM, 1995, ALIMENT PHARM THERAP, V9, P209